In response to a growing scandal involving illegal kidney transplants, Islamabad has temporarily banned all organ transplants in both public and private hospitals. The Human Organ Transplant Authority (HOTA) announced the suspension due to non-compliance with regulations under the HOTA Act 2010. This decision aims to enforce ethical medical practices and prevent further violations.
HOTA Enforces Stricter Regulations
HOTA has issued formal letters to hospitals in Islamabad, suspending their transplant units for failing to establish mandatory evaluation committees. These committees, required under organ transplant laws, ensure compliance with ethical and legal standards. Despite repeated directives, several hospitals disregarded these requirements, prompting the temporary ban.
The authority had initially directed hospitals to form evaluation committees by November 30, 2024. However, widespread non-compliance led to this decisive action. HOTA emphasized that the absence of these committees creates significant ethical and legal risks in organ transplant procedures.
Notices Issued Before Suspension
HOTA had previously warned hospitals through notices issued on November 20, 2024. The notices outlined the urgent need to establish evaluation committees to oversee transplant activities. Despite these warnings, both public and private hospitals continued to violate the directives, forcing the authority to halt all transplant procedures temporarily.
HOTA has stated that this suspension will remain in place until further notice. It has also warned that hospitals failing to comply will face strict disciplinary actions.
Ethical Concerns and Legal Challenges
The scandal surrounding illegal kidney transplants has raised serious ethical and legal questions. The absence of proper oversight has created an environment where violations of organ transplant laws can occur unchecked. HOTA’s decision reflects a commitment to addressing these concerns and safeguarding patients’ rights.
Read: Deadly “Disease X” Outbreak in Congo Sparks Global Concern
Broader Crackdown on Substandard Medicines
In a related development, the Drug Regulatory Authority of Pakistan (DRAP) recently imposed a nationwide ban on eight batches of counterfeit and substandard medicines. The affected drugs, used for diabetes and other critical treatments, were found to have questionable quality and efficacy.
Details of the Banned Medicines
The Central Drug Testing Lab in Karachi identified these batches as substandard after thorough testing. The banned medicines include diabetes tablet Amplemet XR (Batch 39224), antibiotic injection Esanix (Batch IA702), and bacterial infection medicine Flagenis Suspension (Batch 0362). Other banned products include Vitamin B12 infusions Cyanoco Infusion (Batch 6609) and Cyanoco Super (Batch 6403), among others.
Nationwide Measures to Combat Counterfeit Drugs
DRAP has launched a nationwide crackdown to eliminate counterfeit medicines, targeting supply chains in Punjab, Balochistan, and Khyber Pakhtunkhwa. Authorities have confiscated the affected batches and called for thorough investigations into their production and distribution.
Upholding Patient Safety
Both HOTA and DRAP’s actions underline the importance of ethical medical practices and patient safety. As Islamabad navigates this organ transplant crisis, the measures aim to restore public trust in the healthcare system while ensuring that such violations do not occur in the future.
Follow Day News on Google News, Instagram, YouTube, Facebook, Whats App, and TikTok for latest updates
